Dyne Therapeutics (Nasdaq:DYN) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

DYN 주식 개요

임상 단계의 근육 질환 회사인 다인 테라퓨틱스는 미국에서 유전적으로 유발되는 근육 질환의 치료제를 개발하는 생명공학 회사로 운영되고 있습니다.

DYN 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 60.36% 증가할 것으로 예상됩니다.

분석가들은 주가가 38.5% 상승할 것이라는 데 동의합니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

수익이 1백만 달러 미만인 경우 ( $0 )

최근 3개월간 주가 변동성

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Dyne Therapeutics, Inc. 경쟁사

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$3.6b

Crinetics Pharmaceuticals

NasdaqGS:CRNX

US$3.6b

Merus

NasdaqGM:MRUS

US$3.6b

Denali Therapeutics

NasdaqGS:DNLI

US$3.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Dyne Therapeutics
과거 주가
현재 주가	US$35.63
52주 최고치	US$35.98
52주 최저치	US$6.40
베타	1.06
11개월 변경	14.13%
3개월 변경 사항	33.05%
1년 변경 사항	250.17%
33년 변화	59.56%
5년 변화	n/a
IPO 이후 변화	49.08%

최근 뉴스 및 업데이트

Recent updates

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?

Jan 27

Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial

Jan 11

Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial

Jan 08

주주 수익률

	DYN	US Biotechs	US 마켓
7D	12.1%	0.06%	0.1%
1Y	250.2%	9.9%	24.1%

수익률 대 산업: DYN 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: DYN 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is DYN's price volatile compared to industry and market?
DYN volatility
DYN Average Weekly Movement	11.1%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

안정적인 주가: DYN 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: DYN 의 주간 변동성( 11% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2017	143	John Cox	www.dyne-tx.com

임상 단계의 근육 질환 회사인 다인 테라퓨틱스는 미국에서 유전자에 의한 근육 질환 치료제를 개발하는 데 주력하는 생명공학 회사입니다. 이 회사는 질병 조절 치료제를 제공하는 포스 플랫폼을 사용하여 근이영양증 1형, 듀센 근이영양증, 안면 견갑골 근이영양증, 희귀 골격근, 심장 및 대사성 근육 질환 프로그램을 포함한 근육 질환 치료제 포트폴리오를 개발하고 있습니다. 다인 테라퓨틱스는 2017년에 설립되었으며 매사추세츠주 월섬에 본사를 두고 있습니다.

Dyne Therapeutics, Inc. 기본 사항 요약

Dyne Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
DYN 기본 통계
시가총액	US$3.47b
수익(TTM)	-US$257.40m
수익(TTM)	n/a

0.0x

P/S 비율

-13.7x

P/E 비율

DYN 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
DYN 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$257.40m
수익	-US$257.40m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.60
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

DYN 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

DYN 주식 개요

보상

위험 분석

Dyne Therapeutics, Inc. 경쟁사

NasdaqGS:RARE

US$3.6b

NasdaqGS:CRNX

US$3.6b

NasdaqGM:MRUS

US$3.6b

NasdaqGS:DNLI

US$3.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Recent updates

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors